WebFeb 2, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors … WebFeb 2, 2024 · Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator. Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal …
Jennifer Laux - Vice President, Marketing
WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by … WebFeb 1, 2024 · Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and … solace mortuary ca
Ascidian Therapeutics Announces Three Key Development Team …
WebApr 11, 2024 · 12 analysts have issued twelve-month price targets for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they expect the company's stock price to reach $56.21 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View analysts price targets for CYTK or view top ... WebMar 6, 2012 · Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the European Medicines Agency (EMA) has granted the company's fast skeletal muscle troponin activator CK-2024357 orphan medicinal product designation for the treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease.CK … WebFeb 28, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in … slugterra burpy coloring pages